Commercial Manufacturing of H1N1 ‘Swine Flu’ Vaccine Underway
Approximately 100,000 doses can be manufactured per week
Following bulk production, the vaccine will undergo routine quality tests, the longest of which will require up to one month. Thus, by mid-July the vaccine should be ready to be used in clinical trials and/or for vaccinations in countries that grant regulatory clearance.
PSC also announced that it will begin shipping H1N1 protein for research use to customers with pre-orders. Orders may be placed on the Company’s website (www.proteinsciences.com).
PSC is in late stage discussions with various parties in
PSC is a privately held biopharmaceutical company based in
PSC’s lead product is FluBlok(R), a seasonal recombinant trivalent influenza vaccine consisting of influenza hemagglutinin proteins. FluBlok is manufactured without the use of eggs, is highly purified and, therefore, does not require the use of thimerosal or antibiotics, and is low in endotoxins. PSC filed a Biologics License Application for FluBlok with the FDA in
SOURCE Protein Sciences Corporation